GE HealthCare Technologies (GEHC) Financials

$71.85 -1.25 (-1.71%)

As of 05/20/2025 04:00 PM Eastern

Annual Income Statements for GE HealthCare Technologies

This table shows GE HealthCare Technologies' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021
Net Income / (Loss) Attributable to Common Shareholders	1,993	1,385	1,916	2,247
Consolidated Net Income / (Loss)	2,050	1,614	1,967	2,293
Net Income / (Loss) Continuing Operations	2,050	1,618	1,949	2,275
Total Pre-Tax Income	2,581	2,361	2,512	2,875
Total Operating Income	2,625	2,435	2,522	2,795
Total Gross Profit	8,205	7,922	7,179	7,174
Total Revenue	19,672	19,552	18,341	17,585
Operating Revenue	19,672	19,552	18,341	17,585
Total Cost of Revenue	11,467	11,630	11,162	10,411
Operating Cost of Revenue	11,467	11,630	11,162	10,411
Total Operating Expenses	5,580	5,487	4,657	4,379
Selling, General & Admin Expense	4,269	4,282	3,631	3,563
Research & Development Expense	1,311	1,205	1,026	816
Total Other Income / (Expense), net	-43	-74	-10	80
Interest Expense	504	542	77	40
Other Income / (Expense), net	461	468	67	120
Income Tax Expense	531	743	563	600
Net Income / (Loss) Discontinued Operations	0.00	-4.00	18	18
Preferred Stock Dividends Declared	0.00	183	0.00	0.00
Net Income / (Loss) Attributable to Noncontrolling Interest	57	46	51	46
Basic Earnings per Share	$4.37	$3.05	$4.22	$4.95
Weighted Average Basic Shares Outstanding	456M	455M	454M	454M
Diluted Earnings per Share	$4.34	$3.03	$4.22	$4.95
Weighted Average Diluted Shares Outstanding	459M	458M	454M	454M
Weighted Average Basic & Diluted Shares Outstanding	457.30M	455.36M	-	-
Cash Dividends to Common per Share	$0.13	$0.12	-	-

This table shows GE HealthCare Technologies' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	564	721	470	428	374	403	375	418	189	-	487
Consolidated Net Income / (Loss)	588	737	490	435	388	416	382	433	383	-	493
Net Income / (Loss) Continuing Operations	588	737	490	435	388	416	386	433	383	-	493
Total Pre-Tax Income	692	833	658	578	512	609	636	570	546	-	622
Total Operating Income	629	801	676	608	540	689	617	570	559	-	605
Total Gross Profit	2,012	2,275	2,026	2,002	1,902	2,156	1,935	1,940	1,891	-	1,773
Total Revenue	4,777	5,320	4,863	4,839	4,650	5,206	4,822	4,817	4,707	-	4,576
Operating Revenue	4,777	5,320	4,863	4,839	4,650	5,206	4,822	4,817	4,707	-	4,576
Total Cost of Revenue	2,765	3,043	2,838	2,837	2,749	3,050	2,887	2,877	2,816	-	2,803
Operating Cost of Revenue	2,765	3,043	2,838	2,837	2,749	3,050	2,887	2,877	2,816	-	2,803
Total Operating Expenses	1,384	1,474	1,350	1,394	1,362	1,467	1,318	1,370	1,332	-	1,168
Selling, General & Admin Expense	1,040	1,130	1,034	1,067	1,038	1,152	996	1,072	1,062	-	908
Research & Development Expense	344	344	316	327	324	315	322	298	270	-	260
Total Other Income / (Expense), net	63	33	-19	-29	-28	-80	19	0.00	-13	-	17
Interest Expense	110	121	130	131	122	131	138	137	136	-	2.00
Other Income / (Expense), net	173	154	111	102	94	51	157	137	123	-	19
Income Tax Expense	104	96	168	143	124	193	250	137	163	-	129
Net Income / (Loss) Attributable to Noncontrolling Interest	24	17	19	7.00	14	13	7.00	15	11	-	6.00
Basic Earnings per Share	$1.23	$1.58	$1.03	$0.94	$0.82	$0.89	$0.82	$0.92	$0.42	-	$1.07
Weighted Average Basic Shares Outstanding	457M	456M	457M	457M	456M	455M	455M	455M	454M	454M	454M
Diluted Earnings per Share	$1.23	$1.58	$1.02	$0.93	$0.81	$0.89	$0.82	$0.91	$0.41	-	$1.07
Weighted Average Diluted Shares Outstanding	459M	459M	459M	459M	459M	458M	458M	458M	457M	454M	454M
Weighted Average Basic & Diluted Shares Outstanding	457.88M	457.30M	456.87M	456.66M	456.47M	455.36M	455.24M	-	-	0.00	-

This table details how cash moves in and out of GE HealthCare Technologies' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021
Net Change in Cash & Equivalents	387	1,055	890	-451
Net Cash From Operating Activities	1,951	2,101	2,113	1,607
Net Cash From Continuing Operating Activities	1,955	2,101	2,134	1,607
Net Income / (Loss) Continuing Operations	2,050	1,618	1,949	2,275
Consolidated Net Income / (Loss)	2,050	1,614	1,967	2,293
Net Income / (Loss) Discontinued Operations	0.00	-4.00	18	18
Depreciation Expense	268	248	228	225
Amortization Expense	312	362	405	400
Non-Cash Adjustments To Reconcile Net Income	-585	-390	-263	45
Changes in Operating Assets and Liabilities, net	-91	263	-185	-1,338
Net Cash From Discontinued Operating Activities	-4.00	0.00	-21	0.00
Net Cash From Investing Activities	-914	-558	-398	-1,761
Net Cash From Continuing Investing Activities	-914	-558	-398	-1,761
Purchase of Property, Plant & Equipment	-401	-387	-310	-248
Acquisitions	-313	-147	0.00	-1,481
Purchase of Investments	-40	-48	-59	-
Sale of Property, Plant & Equipment	0.00	1.00	4.00	15
Other Investing Activities, net	-160	23	-33	-47
Net Cash From Financing Activities	-573	-478	-822	-263
Net Cash From Continuing Financing Activities	-572	-478	-822	-263
Repayment of Debt	-1,452	-904	-95	-23
Repurchase of Common Equity	0.00	-211	0.00	0.00
Payment of Dividends	-55	-41	0.00	0.00
Issuance of Debt	995	1,994	8,207	-2.00
Issuance of Common Equity	33	34	0.00	-
Other Financing Activities, net	-93	-1,350	-8,934	-238
Effect of Exchange Rate Changes	-77	-10	-3.00	-34
Cash Interest Paid	550	570	0.00	21

This table details how cash moves in and out of GE HealthCare Technologies' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	-416	-679	1,554	-547	59	86	475	-389	883	947	-
Net Cash From Operating Activities	250	913	738	-119	419	1,050	650	-67	468	1,042	-
Net Cash From Continuing Operating Activities	250	913	744	-121	419	1,050	650	-67	468	1,063	-
Net Income / (Loss) Continuing Operations	588	738	489	435	388	416	386	433	383	567	-
Consolidated Net Income / (Loss)	588	738	489	435	388	416	382	433	383	573	-
Depreciation Expense	66	65	66	69	68	60	64	63	61	59	-
Amortization Expense	70	75	77	80	80	84	89	93	96	98	-
Non-Cash Adjustments To Reconcile Net Income	-230	-137	-91	-202	-155	-9.00	-64	-216	-101	-15	-
Changes in Operating Assets and Liabilities, net	-244	171	203	-503	38	499	175	-440	29	354	-
Net Cash From Investing Activities	-407	-240	-137	-349	-188	-88	-120	-84	-266	-95	-
Net Cash From Continuing Investing Activities	-407	-240	-137	-350	-187	-88	-120	-84	-266	-95	-
Purchase of Property, Plant & Equipment	-152	-102	-90	-64	-145	-94	-80	-70	-143	-77	-
Acquisitions	-269	-54	-	-259	0.00	-	-	-20	-127	-	-
Purchase of Investments	-20	-7.00	-	-	-	-27	-	-	-	-	-
Other Investing Activities, net	34	-77	-14	-27	-42	33	-19	5.00	4.00	40	-
Net Cash From Financing Activities	-286	-1,277	914	-57	-153	-900	-24	-227	673	-37	-
Net Cash From Continuing Financing Activities	-286	-1,276	914	-57	-153	-900	-24	-227	673	-37	-
Repayment of Debt	-263	-1,262	-7.00	-42	-141	-871	-33	1.00	-1.00	-2.00	-
Payment of Dividends	-16	-14	-13	-14	-14	-13	-14	-14	0.00	-	-
Issuance of Debt	1.00	1.00	993	-1.00	2.00	-17	23	-3.00	1,991	8,196	-
Issuance of Common Equity	20	2.00	-	-	-	3.00	-	-	-	-	-
Other Financing Activities, net	-28	-3.00	-90	-	0.00	-2.00	-31	-	-1,317	-8,231	-
Effect of Exchange Rate Changes	27	-75	39	-22	-19	24	-31	-11	8.00	37	-
Cash Interest Paid	78	211	65	219	55	252	68	208	42	-	-

This table presents GE HealthCare Technologies' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Total Assets	33,089	32,454	27,539
Total Current Assets	9,901	9,410	8,318
Cash & Equivalents	2,889	2,504	1,445
Accounts Receivable	3,569	3,557	3,312
Inventories, net	1,939	1,960	2,155
Other Current Assets	1,503	1,389	1,406
Plant, Property, & Equipment, net	2,550	2,500	2,314
Total Noncurrent Assets	20,638	20,544	16,907
Goodwill	13,136	12,936	12,813
Intangible Assets	1,078	1,253	1,520
Noncurrent Deferred & Refundable Income Taxes	4,474	4,474	1,550
Other Noncurrent Operating Assets	1,950	1,881	1,024
Total Liabilities & Shareholders' Equity	33,089	32,454	27,539
Total Liabilities	24,437	25,144	17,947
Total Current Liabilities	9,553	8,981	7,191
Short-Term Debt	1,502	1,006	15
Accounts Payable	3,022	2,947	2,944
Current Employee Benefit Liabilities	1,521	1,518	-
Other Current Liabilities	3,508	3,510	4,232
Total Noncurrent Liabilities	14,884	16,163	10,756
Long-Term Debt	7,449	8,436	8,234
Noncurrent Deferred & Payable Income Tax Liabilities	56	68	370
Noncurrent Employee Benefit Liabilities	5,583	5,782	549
Other Noncurrent Operating Liabilities	1,796	1,877	1,603
Commitments & Contingencies	0.00	0.00	0.00
Redeemable Noncontrolling Interest	188	165	230
Total Equity & Noncontrolling Interests	8,464	7,145	9,362
Total Preferred & Common Equity	8,446	7,133	9,357
Total Common Equity	8,446	7,133	9,357
Common Stock	6,588	6,498	0.00
Retained Earnings	3,262	1,326	0.00
Treasury Stock	-25	0.00	-
Accumulated Other Comprehensive Income / (Loss)	-1,379	-691	-1,878
Noncontrolling Interest	18	12	5.00

This table presents GE HealthCare Technologies' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q4 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	12/31/2022
Total Assets	33,586	33,089	33,855	31,852	32,208	32,454	32,382	27,539
Total Current Assets	9,735	9,901	10,638	8,806	9,373	9,410	9,468	8,318
Cash & Equivalents	2,473	2,889	3,568	2,015	2,563	2,504	2,418	1,445
Accounts Receivable	3,572	3,569	3,424	3,354	3,344	3,557	3,400	3,312
Inventories, net	2,158	1,939	2,124	2,023	1,989	1,960	2,128	2,155
Other Current Assets	1,532	1,503	1,522	1,414	1,478	1,389	1,522	1,406
Plant, Property, & Equipment, net	2,851	2,550	2,539	2,458	2,445	2,500	2,355	2,314
Total Noncurrent Assets	20,999	20,638	20,677	20,589	20,392	20,544	20,559	16,907
Goodwill	13,373	13,136	13,138	13,116	12,927	12,936	12,914	12,813
Intangible Assets	1,238	1,078	1,132	1,195	1,174	1,253	1,332	1,520
Noncurrent Deferred & Refundable Income Taxes	4,462	4,474	4,309	4,365	4,413	4,474	4,277	1,550
Other Noncurrent Operating Assets	1,926	1,950	2,098	1,913	1,878	1,881	2,036	1,024
Total Liabilities & Shareholders' Equity	33,586	33,089	33,855	31,852	32,208	32,454	32,382	27,539
Total Liabilities	24,168	24,437	25,343	23,858	24,609	25,144	25,079	17,947
Total Current Liabilities	9,969	9,553	8,670	8,318	8,859	8,981	7,565	7,191
Short-Term Debt	2,002	1,502	1,007	1,007	1,008	1,006	7.00	15
Accounts Payable	3,152	3,022	2,911	2,824	2,931	2,947	2,774	2,944
Current Employee Benefit Liabilities	1,343	1,521	1,422	1,235	-	1,518	-	-
Other Current Liabilities	3,472	3,508	3,331	3,251	4,920	3,510	4,784	4,232
Total Noncurrent Liabilities	14,199	14,884	16,673	15,539	15,751	16,163	17,514	10,756
Long-Term Debt	6,757	7,449	9,306	8,233	8,247	8,436	10,253	8,234
Noncurrent Deferred & Payable Income Tax Liabilities	159	56	59	55	68	68	62	370
Noncurrent Employee Benefit Liabilities	5,443	5,583	5,388	5,455	5,625	5,782	5,373	549
Other Noncurrent Operating Liabilities	1,840	1,796	1,920	1,796	1,811	1,877	1,826	1,603
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Redeemable Noncontrolling Interest	211	188	177	177	177	165	161	230
Total Equity & Noncontrolling Interests	9,207	8,464	8,335	7,817	7,423	7,145	7,142	9,362
Total Preferred & Common Equity	9,187	8,446	8,317	7,801	7,408	7,133	7,131	9,357
Total Common Equity	9,188	8,446	8,318	7,801	7,409	7,133	7,131	9,357
Common Stock	6,602	6,588	6,556	6,545	6,509	6,498	6,474	0.00
Retained Earnings	3,810	3,262	2,558	2,101	1,687	1,326	937	0.00
Treasury Stock	-25	-25	-25	-	-	0.00	-	-
Accumulated Other Comprehensive Income / (Loss)	-1,199	-1,379	-771	-845	-787	-691	-280	-1,878
Noncontrolling Interest	20	18	18	16	14	12	11	5.00

This table displays calculated financial ratios and metrics derived from GE HealthCare Technologies' official financial filings.

Metric	2024	2023	2022	2021
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021
Growth Metrics	-	-	-	-
Revenue Growth	0.61%	6.60%	4.30%	0.00%
EBITDA Growth	4.36%	9.03%	-8.98%	0.00%
EBIT Growth	6.30%	12.13%	-11.18%	0.00%
NOPAT Growth	24.94%	-14.72%	-11.53%	0.00%
Net Income Growth	27.01%	-17.95%	-14.22%	0.00%
EPS Growth	43.23%	-28.20%	-14.75%	0.00%
Operating Cash Flow Growth	-7.14%	-0.57%	31.49%	0.00%
Free Cash Flow Firm Growth	-57.56%	126.43%	0.00%	0.00%
Invested Capital Growth	3.26%	-13.10%	0.00%	0.00%
Revenue Q/Q Growth	0.58%	0.00%	0.00%	0.00%
EBITDA Q/Q Growth	6.11%	463.88%	0.00%	0.00%
EBIT Q/Q Growth	7.49%	0.00%	0.00%	0.00%
NOPAT Q/Q Growth	13.10%	0.00%	0.00%	0.00%
Net Income Q/Q Growth	18.57%	0.00%	0.00%	0.00%
EPS Q/Q Growth	18.90%	0.00%	0.00%	0.00%
Operating Cash Flow Q/Q Growth	-6.56%	0.38%	0.00%	0.00%
Free Cash Flow Firm Q/Q Growth	-6.55%	0.00%	0.00%	0.00%
Invested Capital Q/Q Growth	-3.55%	-5.92%	0.00%	0.00%
Profitability Metrics	-	-	-	-
Gross Margin	41.71%	40.52%	39.14%	40.80%
EBITDA Margin	18.64%	17.97%	17.57%	20.13%
Operating Margin	13.34%	12.45%	13.75%	15.89%
EBIT Margin	15.69%	14.85%	14.12%	16.58%
Profit (Net Income) Margin	10.42%	8.25%	10.72%	13.04%
Tax Burden Percent	79.43%	68.36%	78.30%	79.76%
Interest Burden Percent	83.64%	81.33%	97.03%	98.63%
Effective Tax Rate	20.57%	31.47%	22.41%	20.87%
Return on Invested Capital (ROIC)	14.40%	10.89%	23.87%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	13.86%	10.09%	24.17%	0.00%
Return on Net Nonoperating Assets (RNNOA)	11.29%	8.21%	17.14%	0.00%
Return on Equity (ROE)	25.69%	19.10%	41.01%	0.00%
Cash Return on Invested Capital (CROIC)	11.19%	24.91%	-176.13%	0.00%
Operating Return on Assets (OROA)	9.42%	9.68%	9.40%	0.00%
Return on Assets (ROA)	6.26%	5.38%	7.14%	0.00%
Return on Common Equity (ROCE)	25.07%	18.63%	40.01%	0.00%
Return on Equity Simple (ROE_SIMPLE)	24.27%	22.63%	21.02%	0.00%
Net Operating Profit after Tax (NOPAT)	2,085	1,669	1,957	2,212
NOPAT Margin	10.60%	8.53%	10.67%	12.58%
Net Nonoperating Expense Percent (NNEP)	0.54%	0.80%	-0.30%	0.00%
Return On Investment Capital (ROIC_SIMPLE)	11.97%	10.06%	11.11%	-
Cost of Revenue to Revenue	58.29%	59.48%	60.86%	59.20%
SG&A Expenses to Revenue	21.70%	21.90%	19.80%	20.26%
R&D to Revenue	6.66%	6.16%	5.59%	4.64%
Operating Expenses to Revenue	28.37%	28.06%	25.39%	24.90%
Earnings before Interest and Taxes (EBIT)	3,086	2,903	2,589	2,915
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	3,666	3,513	3,222	3,540
Valuation Ratios	-	-	-	-
Price to Book Value (P/BV)	4.20	4.91	0.00	0.00
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	1.80	1.79	0.00	0.00
Price to Earnings (P/E)	17.80	25.29	0.00	0.00
Dividend Yield	0.15%	0.12%	0.00%	0.00%
Earnings Yield	5.62%	3.95%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	2.84	2.96	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	2.12	2.16	0.00	0.00
Enterprise Value to EBITDA (EV/EBITDA)	11.39	12.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	13.53	14.52	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	20.02	25.26	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	21.39	20.06	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	25.77	11.04	0.00	0.00
Leverage & Solvency	-	-	-	-
Debt to Equity	1.03	1.29	0.86	0.00
Long-Term Debt to Equity	0.86	1.15	0.86	0.00
Financial Leverage	0.81	0.81	0.71	0.00
Leverage Ratio	4.11	3.55	2.87	0.00
Compound Leverage Factor	3.43	2.89	2.79	0.00
Debt to Total Capital	50.85%	56.36%	46.24%	0.00%
Short-Term Debt to Total Capital	8.53%	6.01%	0.08%	0.00%
Long-Term Debt to Total Capital	42.32%	50.36%	46.15%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	1.17%	1.06%	1.32%	0.00%
Common Equity to Total Capital	47.98%	42.58%	52.45%	0.00%
Debt to EBITDA	2.44	2.69	2.56	0.00
Net Debt to EBITDA	1.65	1.98	2.11	0.00
Long-Term Debt to EBITDA	2.03	2.40	2.56	0.00
Debt to NOPAT	4.29	5.66	4.22	0.00
Net Debt to NOPAT	2.91	4.16	3.48	0.00
Long-Term Debt to NOPAT	3.57	5.06	4.21	0.00
Altman Z-Score	1.92	1.81	0.00	0.00
Noncontrolling Interest Sharing Ratio	2.40%	2.44%	2.45%	0.00%
Liquidity Ratios	-	-	-	-
Current Ratio	1.04	1.05	1.16	0.00
Quick Ratio	0.68	0.67	0.66	0.00
Cash Flow Metrics	-	-	-	-
Free Cash Flow to Firm (FCFF)	1,620	3,817	-14,439	0.00
Operating Cash Flow to CapEx	486.53%	544.30%	690.52%	689.70%
Free Cash Flow to Firm to Interest Expense	3.21	7.04	-187.52	0.00
Operating Cash Flow to Interest Expense	3.87	3.88	27.44	40.18
Operating Cash Flow Less CapEx to Interest Expense	3.08	3.16	23.47	34.35
Efficiency Ratios	-	-	-	-
Asset Turnover	0.60	0.65	0.67	0.00
Accounts Receivable Turnover	5.52	5.69	5.54	0.00
Inventory Turnover	5.88	5.65	5.18	0.00
Fixed Asset Turnover	7.79	8.12	7.93	0.00
Accounts Payable Turnover	3.84	3.95	3.79	0.00
Days Sales Outstanding (DSO)	66.11	64.12	65.91	0.00
Days Inventory Outstanding (DIO)	62.05	64.57	70.47	0.00
Days Payable Outstanding (DPO)	95.00	92.44	96.27	0.00
Cash Conversion Cycle (CCC)	33.16	36.25	40.11	0.00
Capital & Investment Metrics	-	-	-	-
Invested Capital	14,713	14,248	16,396	0.00
Invested Capital Turnover	1.36	1.28	2.24	0.00
Increase / (Decrease) in Invested Capital	465	-2,148	16,396	0.00
Enterprise Value (EV)	41,741	42,147	0.00	0.00
Market Capitalization	35,473	35,032	0.00	0.00
Book Value per Share	$18.49	$15.67	$20.61	$0.00
Tangible Book Value per Share	($12.63)	($15.50)	($10.96)	$0.00
Total Capital	17,603	16,752	17,841	0.00
Total Debt	8,951	9,442	8,249	0.00
Total Long-Term Debt	7,449	8,436	8,234	0.00
Net Debt	6,062	6,938	6,804	0.00
Capital Expenditures (CapEx)	401	386	306	233
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-1,039	-1,069	-303	0.00
Debt-free Net Working Capital (DFNWC)	1,850	1,435	1,142	0.00
Net Working Capital (NWC)	348	429	1,127	0.00
Net Nonoperating Expense (NNE)	35	55	-10	-81
Net Nonoperating Obligations (NNO)	6,061	6,938	6,804	0.00
Total Depreciation and Amortization (D&A)	580	610	633	625
Debt-free, Cash-free Net Working Capital to Revenue	-5.28%	-5.47%	-1.65%	0.00%
Debt-free Net Working Capital to Revenue	9.40%	7.34%	6.23%	0.00%
Net Working Capital to Revenue	1.77%	2.19%	6.14%	0.00%
Earnings Adjustments	-	-	-	-
Adjusted Basic Earnings per Share	$4.37	$3.05	$0.00	$0.00
Adjusted Weighted Average Basic Shares Outstanding	456M	455M	0.00	0.00
Adjusted Diluted Earnings per Share	$4.34	$3.03	$0.00	$0.00
Adjusted Weighted Average Diluted Shares Outstanding	459M	458M	0.00	0.00
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	457.30M	455.36M	0.00	0.00
Normalized Net Operating Profit after Tax (NOPAT)	2,085	1,669	1,957	2,212
Normalized NOPAT Margin	10.60%	8.53%	10.67%	12.58%
Pre Tax Income Margin	13.12%	12.08%	13.70%	16.35%
Debt Service Ratios	-	-	-	-
EBIT to Interest Expense	6.12	5.36	33.62	72.88
NOPAT to Interest Expense	4.14	3.08	25.41	55.29
EBIT Less CapEx to Interest Expense	5.33	4.64	29.65	67.05
NOPAT Less CapEx to Interest Expense	3.34	2.37	21.44	49.47
Payout Ratios	-	-	-	-
Dividend Payout Ratio	2.68%	2.54%	0.00%	0.00%
Augmented Payout Ratio	2.68%	15.61%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from GE HealthCare Technologies' official financial filings.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	2.73%	2.19%	0.85%	0.46%	-1.21%	0.00%	5.38%	0.00%	0.00%	0.00%	0.00%
EBITDA Growth	19.95%	23.87%	0.32%	-0.46%	-6.79%	463.06%	48.56%	0.00%	0.00%	0.00%	0.00%
EBIT Growth	26.50%	29.05%	1.68%	0.42%	-7.04%	0.00%	24.04%	0.00%	0.00%	0.00%	0.00%
NOPAT Growth	30.61%	50.58%	34.43%	5.68%	4.36%	0.00%	-21.91%	0.00%	0.00%	0.00%	0.00%
Net Income Growth	51.55%	77.16%	28.27%	0.46%	1.31%	0.00%	-22.52%	0.00%	0.00%	0.00%	0.00%
EPS Growth	51.85%	77.53%	24.39%	2.20%	97.56%	0.00%	-23.36%	0.00%	0.00%	0.00%	0.00%
Operating Cash Flow Growth	-40.33%	-13.05%	13.54%	-77.61%	-10.47%	0.77%	0.00%	0.00%	0.00%	0.00%	0.00%
Free Cash Flow Firm Growth	93.69%	-90.69%	102.66%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Invested Capital Growth	9.87%	3.26%	0.73%	0.00%	0.00%	-13.10%	0.00%	0.00%	0.00%	0.00%	0.00%
Revenue Q/Q Growth	-10.21%	9.40%	0.50%	4.06%	0.00%	7.96%	0.10%	2.34%	0.00%	0.00%	0.00%
EBITDA Q/Q Growth	-14.34%	17.74%	8.27%	9.85%	443.06%	-4.64%	7.42%	2.86%	434.39%	-74.84%	0.00%
EBIT Q/Q Growth	-16.02%	21.35%	10.85%	11.99%	0.00%	-4.39%	9.48%	3.67%	0.00%	-100.00%	0.00%
NOPAT Q/Q Growth	-24.58%	40.78%	10.02%	11.82%	0.00%	25.68%	-13.52%	10.43%	0.00%	-100.00%	0.00%
Net Income Q/Q Growth	-20.22%	50.41%	12.64%	12.11%	0.00%	8.90%	-11.78%	13.05%	0.00%	0.00%	0.00%
EPS Q/Q Growth	-22.15%	54.90%	9.68%	14.81%	0.00%	8.54%	-9.89%	121.95%	0.00%	0.00%	0.00%
Operating Cash Flow Q/Q Growth	-72.62%	23.71%	720.17%	-128.40%	-60.10%	61.54%	1,070.15%	-114.32%	-55.09%	0.00%	0.00%
Free Cash Flow Firm Q/Q Growth	-459.28%	-38.06%	102.66%	-6.34%	-746.36%	117.73%	0.00%	0.00%	0.00%	0.00%	0.00%
Invested Capital Q/Q Growth	6.73%	-3.55%	0.22%	6.50%	0.32%	-5.92%	0.00%	0.00%	-100.00%	0.00%	0.00%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	42.12%	42.76%	41.66%	41.37%	40.90%	41.41%	40.13%	40.27%	40.17%	0.00%	38.75%
EBITDA Margin	19.64%	20.58%	19.12%	17.75%	16.82%	16.98%	19.22%	17.92%	17.82%	0.00%	13.64%
Operating Margin	13.17%	15.06%	13.90%	12.56%	11.61%	13.23%	12.80%	11.83%	11.88%	0.00%	13.22%
EBIT Margin	16.79%	17.95%	16.18%	14.67%	13.63%	14.21%	16.05%	14.68%	14.49%	0.00%	13.64%
Profit (Net Income) Margin	12.31%	13.85%	10.08%	8.99%	8.34%	7.99%	7.92%	8.99%	8.14%	0.00%	10.77%
Tax Burden Percent	84.97%	88.48%	74.47%	75.26%	75.78%	68.31%	60.06%	75.96%	70.15%	0.00%	79.26%
Interest Burden Percent	86.28%	87.23%	83.61%	81.41%	80.76%	82.30%	82.17%	80.62%	80.06%	0.00%	99.68%
Effective Tax Rate	15.03%	11.52%	25.53%	24.74%	24.22%	31.69%	39.31%	24.04%	29.85%	0.00%	20.74%
Return on Invested Capital (ROIC)	14.77%	18.10%	13.32%	24.25%	24.01%	11.54%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	15.59%	18.53%	13.14%	23.62%	23.37%	10.74%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	11.89%	15.09%	12.11%	21.36%	20.58%	8.73%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	26.66%	33.19%	25.43%	45.61%	44.59%	20.27%	0.00%	0.00%	0.00%	0.00%	0.00%
Cash Return on Invested Capital (CROIC)	5.35%	11.19%	11.40%	-177.56%	-176.42%	24.91%	0.00%	0.00%	0.00%	-88.07%	0.00%
Operating Return on Assets (OROA)	10.10%	10.78%	9.56%	17.98%	16.51%	9.27%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Assets (ROA)	7.41%	8.32%	5.95%	11.02%	10.10%	5.21%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Common Equity (ROCE)	26.00%	32.39%	24.85%	44.51%	43.47%	19.78%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity Simple (ROE_SIMPLE)	24.49%	0.00%	20.79%	20.78%	21.85%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	534	709	503	458	409	471	374	433	392	0.00	480
NOPAT Margin	11.19%	13.32%	10.35%	9.46%	8.80%	9.04%	7.77%	8.99%	8.33%	0.00%	10.48%
Net Nonoperating Expense Percent (NNEP)	-0.83%	-0.44%	0.18%	0.62%	0.63%	0.80%	-0.19%	0.00%	0.00%	0.00%	0.00%
Return On Investment Capital (ROIC_SIMPLE)	2.97%	4.07%	-	-	-	2.84%	-	-	-	0.00%	-
Cost of Revenue to Revenue	57.88%	57.20%	58.36%	58.63%	59.12%	58.59%	59.87%	59.73%	59.83%	0.00%	61.25%
SG&A Expenses to Revenue	21.77%	21.24%	21.26%	22.05%	22.32%	22.13%	20.66%	22.25%	22.56%	0.00%	19.84%
R&D to Revenue	7.20%	6.47%	6.50%	6.76%	6.97%	6.05%	6.68%	6.19%	5.74%	0.00%	5.68%
Operating Expenses to Revenue	28.97%	27.71%	27.76%	28.81%	29.29%	28.18%	27.33%	28.44%	28.30%	0.00%	25.52%
Earnings before Interest and Taxes (EBIT)	802	955	787	710	634	740	774	707	682	0.00	624
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	938	1,095	930	859	782	884	927	863	839	157	624
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	3.99	4.20	5.12	4.53	5.57	4.91	4.32	0.00	0.00	0.00	0.00
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	1.85	1.80	2.18	1.81	2.12	1.79	0.00	0.00	0.00	0.00	0.00
Price to Earnings (P/E)	16.77	17.80	25.43	22.38	26.28	25.29	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.16%	0.15%	0.13%	0.19%	0.13%	0.12%	0.09%	0.04%	0.00%	0.00%	0.00%
Earnings Yield	5.96%	5.62%	3.93%	4.47%	3.81%	3.95%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	2.75	2.84	3.25	2.81	3.37	2.96	2.56	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	2.18	2.12	2.53	2.19	2.47	2.16	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBITDA (EV/EBITDA)	11.29	11.39	14.33	12.39	13.93	12.00	62.34	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	13.26	13.53	17.25	14.97	16.86	14.52	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	19.50	20.02	26.87	25.05	28.57	25.26	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	24.21	21.39	23.72	21.39	23.46	20.06	18.56	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	53.80	25.77	28.57	0.00	0.00	11.04	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.93	1.03	1.21	1.16	1.22	1.29	1.40	0.00	0.00	0.86	0.00
Long-Term Debt to Equity	0.72	0.86	1.09	1.03	1.09	1.15	1.40	0.00	0.00	0.86	0.00
Financial Leverage	0.76	0.81	0.92	0.90	0.88	0.81	1.07	0.00	0.00	0.71	0.00
Leverage Ratio	3.87	4.11	4.19	3.98	4.24	3.55	4.43	0.00	0.00	2.87	0.00
Compound Leverage Factor	3.34	3.58	3.50	3.24	3.42	2.92	3.64	0.00	0.00	0.00	0.00
Debt to Total Capital	48.19%	50.85%	54.78%	53.61%	54.91%	56.36%	58.42%	0.00%	0.00%	46.24%	0.00%
Short-Term Debt to Total Capital	11.01%	8.53%	5.35%	5.84%	5.98%	6.01%	0.04%	0.00%	0.00%	0.08%	0.00%
Long-Term Debt to Total Capital	37.17%	42.32%	49.43%	47.77%	48.93%	50.36%	58.38%	0.00%	0.00%	46.15%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	1.27%	1.17%	1.04%	1.12%	1.13%	1.06%	0.98%	0.00%	0.00%	1.32%	0.00%
Common Equity to Total Capital	50.55%	47.98%	44.19%	45.27%	43.96%	42.58%	40.60%	0.00%	0.00%	52.45%	0.00%
Debt to EBITDA	2.29	2.44	2.98	2.68	2.68	2.69	16.47	0.00	0.00	2.56	0.00
Net Debt to EBITDA	1.64	1.65	1.95	2.09	1.94	1.98	12.59	0.00	0.00	2.11	0.00
Long-Term Debt to EBITDA	1.77	2.03	2.69	2.39	2.39	2.40	16.46	0.00	0.00	2.56	0.00
Debt to NOPAT	3.96	4.29	5.59	5.41	5.49	5.66	0.00	0.00	0.00	4.22	0.00
Net Debt to NOPAT	2.84	2.91	3.66	4.23	3.97	4.16	0.00	0.00	0.00	3.48	0.00
Long-Term Debt to NOPAT	3.06	3.57	5.05	4.82	4.89	5.06	0.00	0.00	0.00	4.21	0.00
Altman Z-Score	1.73	1.71	1.84	1.69	1.77	1.59	0.93	0.00	0.00	0.00	0.00
Noncontrolling Interest Sharing Ratio	2.47%	2.40%	2.31%	2.41%	2.51%	2.44%	2.36%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	0.98	1.04	1.23	1.06	1.06	1.05	1.25	0.00	0.00	1.16	0.00
Quick Ratio	0.61	0.68	0.81	0.65	0.67	0.67	0.77	0.00	0.00	0.66	0.00
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-876	244	393	-14,764	-13,884	2,619	-14,771	0.00	0.00	0.00	0.00
Operating Cash Flow to CapEx	164.47%	895.10%	820.00%	-185.94%	288.97%	1,117.02%	812.50%	-95.71%	327.27%	1,371.05%	0.00%
Free Cash Flow to Firm to Interest Expense	-7.96	2.01	3.03	-112.71	-113.80	19.99	-107.03	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	2.27	7.55	5.68	-0.91	3.43	8.02	4.71	-0.49	3.44	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.89	6.70	4.98	-1.40	2.25	7.30	4.13	-1.00	2.39	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.60	0.60	0.59	1.23	1.21	0.65	0.00	0.00	0.00	0.67	0.00
Accounts Receivable Turnover	5.73	5.52	5.73	0.00	0.00	5.69	0.00	0.00	0.00	5.54	0.00
Inventory Turnover	5.54	5.88	5.40	0.00	0.00	5.65	0.00	0.00	0.00	5.18	0.00
Fixed Asset Turnover	7.48	7.79	7.99	0.00	0.00	8.12	0.00	0.00	0.00	7.93	0.00
Accounts Payable Turnover	3.78	3.84	4.04	0.00	0.00	3.95	0.00	0.00	0.00	3.79	0.00
Days Sales Outstanding (DSO)	63.75	66.11	63.68	0.00	0.00	64.12	0.00	0.00	0.00	65.91	0.00
Days Inventory Outstanding (DIO)	65.91	62.05	67.63	0.00	0.00	64.57	0.00	0.00	0.00	70.47	0.00
Days Payable Outstanding (DPO)	96.68	95.00	90.42	0.00	0.00	92.44	0.00	0.00	0.00	96.27	0.00
Cash Conversion Cycle (CCC)	32.98	33.16	40.88	0.00	0.00	36.25	0.00	0.00	0.00	40.11	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	15,703	14,713	15,255	15,222	14,293	14,248	15,145	0.00	0.00	16,396	0.00
Invested Capital Turnover	1.32	1.36	1.29	2.56	2.73	1.28	0.00	0.00	0.00	1.12	0.00
Increase / (Decrease) in Invested Capital	1,410	465	110	15,222	14,293	-2,148	15,145	0.00	0.00	0.00	0.00
Enterprise Value (EV)	43,134	41,741	49,527	42,775	48,135	42,147	38,840	36,805	37,163	0.00	0.00
Market Capitalization	36,617	35,473	42,587	35,357	41,252	35,032	30,826	36,805	37,163	0.00	0.00
Book Value per Share	$20.09	$18.49	$18.21	$17.09	$16.25	$15.67	$15.67	$0.00	$0.00	$20.61	$0.00
Tangible Book Value per Share	($11.86)	($12.63)	($13.03)	($14.26)	($14.68)	($15.50)	($15.64)	$0.00	$0.00	($10.96)	$0.00
Total Capital	18,177	17,603	18,825	17,234	16,855	16,752	17,563	0.00	0.00	17,841	0.00
Total Debt	8,759	8,951	10,313	9,240	9,255	9,442	10,260	0.00	0.00	8,249	0.00
Total Long-Term Debt	6,757	7,449	9,306	8,233	8,247	8,436	10,253	0.00	0.00	8,234	0.00
Net Debt	6,286	6,062	6,745	7,225	6,692	6,938	7,842	0.00	0.00	6,804	0.00
Capital Expenditures (CapEx)	152	102	90	64	145	94	80	70	143	76	0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-705	-1,039	-593	-520	-1,041	-1,069	-508	0.00	0.00	-303	0.00
Debt-free Net Working Capital (DFNWC)	1,768	1,850	2,975	1,495	1,522	1,435	1,910	0.00	0.00	1,142	0.00
Net Working Capital (NWC)	-234	348	1,968	488	514	429	1,903	0.00	0.00	1,127	0.00
Net Nonoperating Expense (NNE)	-54	-28	13	23	21	55	-7.53	0.00	9.12	0.00	-13
Net Nonoperating Obligations (NNO)	6,285	6,061	6,743	7,228	6,693	6,938	7,842	0.00	0.00	6,804	0.00
Total Depreciation and Amortization (D&A)	136	140	143	149	148	144	153	156	157	157	0.00
Debt-free, Cash-free Net Working Capital to Revenue	-3.56%	-5.28%	-3.03%	-2.66%	-5.34%	-5.47%	0.00%	0.00%	0.00%	-1.65%	0.00%
Debt-free Net Working Capital to Revenue	8.93%	9.40%	15.21%	7.66%	7.81%	7.34%	0.00%	0.00%	0.00%	6.23%	0.00%
Net Working Capital to Revenue	-1.18%	1.77%	10.06%	2.50%	2.64%	2.19%	0.00%	0.00%	0.00%	6.14%	0.00%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$1.23	$1.58	$1.03	$0.94	$0.82	$0.89	$0.82	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic Shares Outstanding	457M	456M	457M	457M	456M	455M	455M	0.00	0.00	454M	0.00
Adjusted Diluted Earnings per Share	$1.23	$1.58	$1.02	$0.93	$0.81	$0.89	$0.82	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Diluted Shares Outstanding	459M	459M	459M	459M	459M	458M	458M	0.00	0.00	454M	0.00
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	457.88M	457.30M	456.87M	456.66M	456.47M	455.36M	455.24M	0.00	0.00	0.00	0.00
Normalized Net Operating Profit after Tax (NOPAT)	534	709	503	458	409	471	374	433	392	0.00	480
Normalized NOPAT Margin	11.19%	13.32%	10.35%	9.46%	8.80%	9.04%	7.77%	8.99%	8.33%	0.00%	10.48%
Pre Tax Income Margin	14.49%	15.66%	13.53%	11.94%	11.01%	11.70%	13.19%	11.83%	11.60%	0.00%	13.59%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	7.29	7.89	6.05	5.42	5.20	5.65	5.61	5.16	5.01	0.00	312.00
NOPAT to Interest Expense	4.86	5.86	3.87	3.49	3.35	3.59	2.71	3.16	2.88	0.00	239.76
EBIT Less CapEx to Interest Expense	5.91	7.05	5.36	4.93	4.01	4.93	5.03	4.65	3.96	0.00	312.00
NOPAT Less CapEx to Interest Expense	3.48	5.01	3.18	3.00	2.17	2.88	2.13	2.65	1.83	0.00	239.76
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	2.53%	2.68%	3.12%	3.39%	3.40%	2.54%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	2.53%	2.68%	3.12%	3.39%	3.40%	15.61%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About GE HealthCare Technologies' Financials

When does GE HealthCare Technologies's fiscal year end?

According to the most recent income statement we have on file, GE HealthCare Technologies' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has GE HealthCare Technologies' net income changed over the last 3 years?

GE HealthCare Technologies' net income appears to be on a downward trend, with a most recent value of $2.05 billion in 2024, falling from $2.29 billion in 2021. The previous period was $1.61 billion in 2023. View GE HealthCare Technologies' forecast to see where analysts expect GE HealthCare Technologies to go next.

What is GE HealthCare Technologies's operating income?

GE HealthCare Technologies's total operating income in 2024 was $2.63 billion, based on the following breakdown:

Total Gross Profit: $8.21 billion
Total Operating Expenses: $5.58 billion

How has GE HealthCare Technologies revenue changed over the last 3 years?

Over the last 3 years, GE HealthCare Technologies' total revenue changed from $17.59 billion in 2021 to $19.67 billion in 2024, a change of 11.9%.

How much debt does GE HealthCare Technologies have?

GE HealthCare Technologies' total liabilities were at $24.44 billion at the end of 2024, a 2.8% decrease from 2023, and a 36.2% increase since 2022.

How much cash does GE HealthCare Technologies have?

In the past 2 years, GE HealthCare Technologies' cash and equivalents has ranged from $1.45 billion in 2022 to $2.89 billion in 2024, and is currently $2.89 billion as of their latest financial filing in 2024.

How has GE HealthCare Technologies' book value per share changed over the last 3 years?

Over the last 3 years, GE HealthCare Technologies' book value per share changed from 0.00 in 2021 to 18.49 in 2024, a change of 1,848.7%.

Related Companies

This page (NASDAQ:GEHC) was last updated on 5/21/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

GE HealthCare Technologies (GEHC) Financials

Frequently Asked Questions About GE HealthCare Technologies' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

GE HealthCare Technologies (GEHC) Financials

Annual Income Statements for GE HealthCare Technologies

Quarterly Income Statements for GE HealthCare Technologies

Annual Cash Flow Statements for GE HealthCare Technologies

Quarterly Cash Flow Statements for GE HealthCare Technologies

Annual Balance Sheets for GE HealthCare Technologies

Quarterly Balance Sheets for GE HealthCare Technologies

Annual Metrics And Ratios for GE HealthCare Technologies

Quarterly Metrics And Ratios for GE HealthCare Technologies

Frequently Asked Questions About GE HealthCare Technologies' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools